Longitudinal analysis of stool samples reveals new insights into how the gut microbiome changes during immunotherapy. These findings could inform the application of microbiome-targeted interventions to maximize the outcomes of immune checkpoint blockade.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Baruch, E. et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science 371, 602–609 (2021). This research article assessed the safety and feasibility of ICB combined with fecal microbiota transplantation from ICB-responder donors to patients with ICB-refractory metastatic melanoma.
Routy, B. et al. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial. Nat. Med. 29, 2121–2132 (2023). This research article assessed the safety of ICB combined with fecal microbiota transplantation from healthy donors to ICB-naive patients with advanced melanoma.
Lee, K. A. et al. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. Nat. Med. 28, 535–544 (2022). This meta-analysis of five observational cohorts of ICB-naive patients with advanced melanoma indicates that no single microbial species can be used as a biomarker.
Gilbert, J. et al. Microbiome-wide association studies link dynamic microbial consortia to disease. Nature 535, 94–103 (2016). This review article discusses the importance of moving from a static analysis to a dynamic, functional, analysis of the microbiome.
Derosa, L. et al. Microbiota-centered interventions: the next breakthrough in immuno-oncology? Cancer Discov. 11, 2396–2412 (2021). This review article highlights the potential of microbiota-centered interventions.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Björk, J. R. et al. Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma. Nat. Med. https://doi.org/10.1038/s41591-024-02803-3 (2024).
Rights and permissions
About this article
Cite this article
Longitudinal analysis shows how microbiome changes might influence responses to immune checkpoint blockade. Nat Med 30, 644–645 (2024). https://doi.org/10.1038/s41591-024-02830-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-024-02830-0
